AnaptysBio, Inc.
AnaptysBio, Inc. Fundamental Analysis
AnaptysBio, Inc. (ANAB) shows moderate financial fundamentals with a PE ratio of -136.85, profit margin of -5.64%, and ROE of 18.14%. The company generates $0.2B in annual revenue with weak year-over-year growth of 1.57%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 45.0/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze ANAB's fundamental strength across five key dimensions:
Efficiency Score
WeakANAB struggles to generate sufficient returns from assets.
Valuation Score
ExcellentANAB trades at attractive valuation levels.
Growth Score
ModerateANAB shows steady but slowing expansion.
Financial Health Score
ModerateANAB shows balanced financial health with some risks.
Profitability Score
ModerateANAB maintains healthy but balanced margins.
Key Financial Metrics
Is ANAB Expensive or Cheap?
P/E Ratio
ANAB trades at -136.85 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, ANAB's PEG of -1.52 indicates potential undervaluation.
Price to Book
The market values AnaptysBio, Inc. at 48.66 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 27.28 times EBITDA. This signals the market has high growth expectations.
How Well Does ANAB Make Money?
Net Profit Margin
For every $100 in sales, AnaptysBio, Inc. keeps $-5.64 as profit after all expenses.
Operating Margin
Core operations generate 20.42 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $18.14 in profit for every $100 of shareholder equity.
ROA
AnaptysBio, Inc. generates $-3.63 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
AnaptysBio, Inc. generates limited operating cash flow of $20.38M, signaling weaker underlying cash strength.
Free Cash Flow
AnaptysBio, Inc. produces free cash flow of $20.29M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.71 in free cash annually.
FCF Yield
ANAB converts 1.06% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-136.85
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.52
vs 25 benchmark
P/B Ratio
Price to book value ratio
48.66
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.98
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
7.81
vs 25 benchmark
Current Ratio
Current assets to current liabilities
9.07
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
18.14
vs 25 benchmark
ROA
Return on assets percentage
-0.04
vs 25 benchmark
ROCE
Return on capital employed
0.15
vs 25 benchmark
How ANAB Stacks Against Its Sector Peers
| Metric | ANAB Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -136.85 | 28.25 | Better (Cheaper) |
| ROE | 1813.85% | 780.00% | Excellent |
| Net Margin | -5.64% | -20122.00% (disorted) | Weak |
| Debt/Equity | 7.81 | 0.30 | Weak (High Leverage) |
| Current Ratio | 9.07 | 4.66 | Strong Liquidity |
| ROA | -3.63% | -14687.00% (disorted) | Weak |
ANAB outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROE, but lagging in Net Margin.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews AnaptysBio, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
207.32%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
34.77%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
236.69%
Industry Style: Defensive, Growth, Innovation
High Growth